Gilead’s Sofosbuvir Likely to Get Japan Greenlight as Early as March-End

The Pharmaceutical Affairs and Food Sanitation Council’s Second Committee on Drugs on March 5 recommended approval of Gilead Sciences K.K.’s interferon-free hepatitis C drug sofosbuvir, clearing the way for the health ministry’s official nod as early as the end of...read more